This analysis examines the current position and future outlook for Forest in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-7 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase
Understand why longer-term success depends upon whether Forest can secure further promising in-licensing deals and bring products to market swiftly
Benchmark Forest’s performance against key rivals in the ethical pharmaceuticals sector
Learn how Forest is expected to secure Lexapro’s position in the depression market
